ArticleDiseases (Basel, Switzerland)2024
Indole-3 Carbinol and Diindolylmethane Mitigated β-Amyloid-Induced Neurotoxicity and Acetylcholinesterase Enzyme Activity: In Silico, In Vitro, and Network Pharmacology Study.
Article in Diseases (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Trial
- Apigenin-mediated MARK4 inhibition: a novel approach in advancing Alzheimer's disease therapeutics.Molecular diversity · 2025Article
- Association of APOC1 with cortical atrophy during conversion to Alzheimer's disease.GeroScience · 2025Article
- Evaluating the Neuroprotective and Acetylcholinesterase Inhibitory Properties of Four Calcineurin Inhibitor Drugs: Tacrolimus, Pimecrolimus, Cyclosporin A, and Voclosporin.Molecular neurobiology · 2025Article
- Functionalized nanoparticles based on β-chitosan and styrene copolymer derivative for donepezil delivery.3 Biotech · 2025Article
- Review
- Implicating neuroinflammation in hippocampus, prefrontal cortex and amygdala with cognitive deficit: a narrative review.3 Biotech · 2025Review
- Potential Roles of Natural Antioxidants in Modulating Neurodegenerative Disease Pathways.Molecular neurobiology · 2025Review
- From Molecules to Medicines: The Role of AI-Driven Drug Discovery Against Alzheimer's Disease and Other Neurological Disorders.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Methylphenidate and Modafinil Mitigate Scopolamine-Induced Behavioral Alterations.ACS pharmacology & translational science · 2025Article
- Unraveling novel mechanisms of ATP-Binding cassette (ABC) transporter in insulin Resistance-induced amyloidogenesis.Metabolic brain disease · 2025Review
- Triclosan promotes neurotoxicity in diabetic conditions: an in vivo molecular assessment using zebrafish model.3 Biotech · 2025Article
- Integrated insight and in silico investigation of hybrid3 Biotech · 2025Article
- The role of gut microbiota-derived metabolites in neuroinflammation.Neuroprotection (Chichester, England) · 2025Review
- Article
- The emerging role of chitinase-3-like-1 protein in neurodegeneration.Metabolic brain disease · 2025Review
- Target Identification of Ginsenosides Against Cognitive Impairment by Using Mass Spectrometry-Based Cellular Thermal Shift Assay (CETSA).Neurochemical research · 2025Article
- Article
- Correlation of autophagy and Alzheimer's disease with special emphasis on the role of phosphodiesterase-4.3 Biotech · 2025Review
- Integrating network pharmacology and in vivo study to explore the anti-Alzheimer's potential of3 Biotech · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.